Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | YAP1 | P46937 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872216 | 0.81 | SRD5A2 (0.43) | SRD5A2YAP1LMNAHPGDGPR119 | |
| SCHEMBL2877718 | 0.75 | SRD5A2 (0.49) | SRD5A2YAP1HPGDGPR119SRD5A1 | |
| SCHEMBL19885983 | 0.74 | TLR9 (0.40) | SRD5A2YAP1LMNAHPGDNR1H2 | |
| SCHEMBL2874673 | 0.73 | SRD5A1 (0.41) | SRD5A2LMNAHPGDSRD5A1 | |
| SCHEMBL3035408 | 0.73 | SRD5A2 (0.54) | SRD5A2NR1H2 | |
| SCHEMBL30071177 | 0.70 | NR1H2 (0.45) | NR1H2 | |
| SCHEMBL20494693 | 0.70 | NR1H2 (0.45) | NR1H2 | |
| SCHEMBL18537881 | 0.69 | NR1H2 (0.53) | NR1H2 | |
| SCHEMBL2975720 | 0.69 | MTNR1A (0.42) | SRD5A2PRMT5 | |
| SCHEMBL1423415 | 0.68 | NOD2 (0.42) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966199-B1 | AZAINDOLE-2-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-10-20 | — | — | EP | disclosed |
| US-7622466-B2 | Azaindole-2-carboxamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090005379-A1 | Azaindole-2-Carboxamide Derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1966199-A1 | AZAINDOLE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007057329-A1 | AZAINDOLE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005379-A1 | Azaindole-2-Carboxamide Derivatives | HRH3, HRH4, H1-5 | SRD5A2 1359/4885YAP1 3857/4885LMNA 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.